Compare PRPL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | VTGN |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 10.8M |
| IPO Year | 2015 | 2014 |
| Metric | PRPL | VTGN |
|---|---|---|
| Price | $2.77 | $0.23 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 3 |
| Target Price | $0.65 | ★ $0.90 |
| AVG Volume (30 Days) | 31.5K | ★ 513.6K |
| Earning Date | 04-28-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $468,725,000.00 | N/A |
| Revenue This Year | $8.50 | $124.49 |
| Revenue Next Year | $6.68 | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.20 |
| 52 Week High | $10.00 | $5.14 |
| Indicator | PRPL | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 25.77 | 39.72 |
| Support Level | $0.40 | $0.23 |
| Resistance Level | $10.00 | $0.32 |
| Average True Range (ATR) | 0.23 | 0.01 |
| MACD | -0.16 | 0.00 |
| Stochastic Oscillator | 4.61 | 15.64 |
Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.